Analytical Data
-
Gene name
SMN2
- Application
-
Alternative Names
SMNC; SMNT; SMA2; BCD541; SMA3; SMA4; SMA1; SMA
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q16637
-
Expression Region
Glu16~Pro251
-
Molecular Weight
33kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The study of SMN2 recombinant protein is pivotal in understanding and addressing spinal muscular atrophy (SMA), a genetic disorder characterized by the degeneration of motor neurons, leading to muscle wasting and weakness. SMA is primarily caused by the deficiency of the survival motor neuron (SMN) protein, which is encoded by the SMN1 gene. While humans typically have both SMN1 and SMN2 genes, the SMN2 gene produces a lower amount of functional SMN protein due to alternative splicing. Research efforts have focused on the impact of SMN2 in ameliorating SMA symptoms. The recombinant SMN2 protein can serve as a tool to explore protein interactions, especially in the context of its role in motor neuron survival and function. Additionally, understanding the structural and functional characteristics of SMN2-derived proteins could inform the development of therapeutic strategies, including gene therapy and small molecules aimed at increasing SMN protein levels. Recent advancements in recombinant protein technology have enabled the production of high-quality SMN2 proteins, facilitating biochemical assays and preclinical studies. These studies aid in elucidating the molecular mechanisms of SMA and the potential of SMN2 as a target for novel treatments. The ongoing research in this area holds significant promise for advancing our knowledge of SMA pathophysiology and enhancing therapeutic options for affected individuals.
